Literature DB >> 26671554

The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography.

Lin-Ang Wang1, Xi Wei2, Qing Li3, Lin Chen4.   

Abstract

Gastric cancer is the one of the most common cancers around the world. The prognosis of gastric cancer remains poor, due to the biological characteristics of the primary tumor as well as the recurrence after treatment. Accumulating evidence suggests the implication of programmed death ligand-1 (PD-L1) in the pathogenesis and prognosis of cancer. This study aimed to explore the CEUS as a valuable tool to improve the assessment of the therapeutic effect of the PD-L1 blocker in the treatment of gastric cancer. A total number of 105 patients with gastric cancer were enrolled in this study from June 2008 to December 2011 in our hospital. The association of PD-L1 expression level (105 cases) and CEUS parameters (100 cases) with the prognosis of gastric cancer was examined. The results showed that PD-L1-positive staining was associated with the depth of invasion, differentiation, and poor prognosis of patients with gastric cancer. The CEUS intensity (positive) exhibited poor prognosis compared to the negative counterpart. Moreover, PD-L1 and CEUS co-positivity was significantly related to a poor prognosis. The characteristic of ultrasonography images correlated with the expression of PD-L1 (r = 0.46, P = 0.0003). Collectively, the mean intensity of contrast-enhanced ultrasonography is a useful predictor in the PD-L1 expression in gastric cancer. The ultrasonography and CEUS parameter could be considered as the predictor of response to PD-L1 blocker treatment in the clinical practice.

Entities:  

Keywords:  CEUS; Gastric cancer; Overall survival; PD-L1

Mesh:

Substances:

Year:  2015        PMID: 26671554     DOI: 10.1007/s13277-015-4600-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

Review 1.  Imaging in assessing lymph node status in gastric cancer.

Authors:  Robert Michael Kwee; Thomas Christian Kwee
Journal:  Gastric Cancer       Date:  2009-04-24       Impact factor: 7.370

2.  Contrast-enhanced ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer.

Authors:  Sven A Lang; Christian Moser; Sebastian Gehmert; Karin Pfister; Christina Hackl; Andreas A Schnitzbauer; Christian Stroszczynski; Hans J Schlitt; Edward K Geissler; Ernst M Jung
Journal:  Clin Hemorheol Microcirc       Date:  2014       Impact factor: 2.375

3.  Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.

Authors:  Ying Li; Xi Wei; Sheng Zhang; Jin Zhang
Journal:  Tumour Biol       Date:  2015-06-09

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Authors:  C Krupka; P Kufer; R Kischel; G Zugmaier; F S Lichtenegger; T Köhnke; B Vick; I Jeremias; K H Metzeler; T Altmann; S Schneider; M Fiegl; K Spiekermann; P A Bauerle; W Hiddemann; G Riethmüller; M Subklewe
Journal:  Leukemia       Date:  2015-08-04       Impact factor: 11.528

7.  Cancer risks attributable to low doses of ionizing radiation: assessing what we really know.

Authors:  David J Brenner; Richard Doll; Dudley T Goodhead; Eric J Hall; Charles E Land; John B Little; Jay H Lubin; Dale L Preston; R Julian Preston; Jerome S Puskin; Elaine Ron; Rainer K Sachs; Jonathan M Samet; Richard B Setlow; Marco Zaider
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

8.  Evaluation of microvascularization in focal salivary gland lesions by contrast-enhanced ultrasonography (CEUS) and Color Doppler sonography.

Authors:  Xi Wei; Ying Li; Sheng Zhang; Xubin Li; Hailing Wang; Xu Yong; Xiaoqing Wang; Xing Li; Ming Gao
Journal:  Clin Hemorheol Microcirc       Date:  2013-01-01       Impact factor: 2.375

9.  Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.

Authors:  Yi Qing; Qing Li; Tao Ren; Wei Xia; Yu Peng; Gao-Lei Liu; Hao Luo; Yu-Xin Yang; Xiao-Yan Dai; Shu-Feng Zhou; Dong Wang
Journal:  Drug Des Devel Ther       Date:  2015-02-16       Impact factor: 4.162

10.  Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer.

Authors:  Fabio Piscaglia; Francesco Corradi; Mikaela Mancini; Francesco Giangregorio; Stefano Tamberi; Giampaolo Ugolini; Bruno Cola; Alberto Bazzocchi; Roberto Righini; Patrizia Pini; Fabio Fornari; Luigi Bolondi
Journal:  BMC Cancer       Date:  2007-09-03       Impact factor: 4.430

View more
  6 in total

1.  Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.

Authors:  Zhebing Qiu; Yinguo Du
Journal:  J Gastrointest Oncol       Date:  2021-02

Review 2.  Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.

Authors:  Xiaojun Liu; Zhongxia Yang; Olivier Latchoumanin; Liang Qiao
Journal:  Therap Adv Gastroenterol       Date:  2016-07-21       Impact factor: 4.409

3.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.

Authors:  Minghui Zhang; Yuandi Dong; Haitao Liu; Yan Wang; Shu Zhao; Qijia Xuan; Yan Wang; Qingyuan Zhang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 4.  Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.

Authors:  Mohamed Abozeid; Antonio Rosato; Roberta Sommaggio
Journal:  Biomed Res Int       Date:  2017-07-11       Impact factor: 3.411

5.  Contrast-Enhanced Ultrasound Parameters and D-Dimer: New Prognostic Parameters for Diffuse Large B-Cell Lymphoma.

Authors:  Shaobo Duan; Ye Zhang; Shuang Xu; Pei Jiang; Qinghua Qi
Journal:  Cancer Manag Res       Date:  2022-08-26       Impact factor: 3.602

6.  Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.

Authors:  Cong Dai; Meng Wang; Jun Lu; Zhiming Dai; Shuai Lin; Pengtao Yang; Tian Tian; Xinghan Liu; Weili Min; Zhijun Dai
Journal:  Onco Targets Ther       Date:  2017-07-21       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.